Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada Title Grant Type Focus Area Country Application Due Date Treatment Optimization in ALK-positive Metastatic Non-Small Cell Lung CancerRelease Date:Education Oncology Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Iceland, Italy, Netherlands, Norway, Portugal, Spain, Swaziland, Sweden, USA, United Kingdom Immunotherapy in High-risk Non-Muscle Invasive Bladder CancerRelease Date:Education Oncology USA Advances in Migraine TreatmentRelease Date:Education Internal Medicine All 2022/2023 Global Obesity ASPIRERelease Date:Research Internal Medicine All Evolving Concepts in Biosimilar Optimization in Inflammatory DiseasesRelease Date:Education Inflammation & Immunology USA Underlying medical conditions and other risk factors, higher risk of severe COVID-19 (European)Release Date:Education Hospital All Building Capacity to Address Health Disparities in the US through AMS Telehealth and Tele-mentoringRelease Date:Quality Improvement Hospital USA 2022/2023 Global NASH ASPIRERelease Date:Research Internal Medicine All 2023 Growth Hormone ResearchRelease Date:Research Rare Disease All Antimicrobial Resistance Testing and Stewardship to Improve Hospitalized Patients’ Health OutcomesRelease Date:Quality Improvement Hospital All Medication Error Reduction Strategies in the Hospital SettingRelease Date:Education Hospital USA 2022/2023 Global Cachexia ASPIRERelease Date:Research Internal Medicine All